סינמט סי.אר - Sinemet cr
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | N04BA Dopa and dopa derivatives | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) |  | |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | ×××××ת ×ש×ר×ר ×××קר, TABLETS CONTROLLED RELEASE ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Idiopathic parkinson's disease. Postencephalitic parkinsonism. Symptomatic parkinsonism. To reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances. | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||||||||||
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ס×× ×× ×¡×.×ר ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ORGANON LLC, USA |
| ×©× ××¢× ×ר×ש×× | ORGANON PHARMA ISRAEL LTD., ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 9/2016. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 17/05/2024 |
השינוי האחרון נעשה בֹ־17 במאי 2024 ב־13:26